


# Discovery of a First in Class MDM2 Degrader for the Treatment of Relapsed/Refractory TP53 Wt AML & Solid Tumors

## Stefanie Schalm, Ph.D. - Senior Director, Oncology



October 26, 2022

## **Forward-looking Statements**

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA) and other federal securities laws. These statements include information about our current and future prospects and our operations and financial results, which are based on currently available information. All statements other than statements of historical facts contained in this presentation, including express or implied statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "positioned," "potential," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include statements about the initiation, timing, progress and results of our current and future clinical trials and current and future preclinical studies of our product candidates and of our research and development programs; our plans to develop and commercialize our current product candidates and any future product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. You should not rely upon forward-looking statements as predictions of future events.

Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, the occurrence of certain events or otherwise. As a result of these risks and others, including those set forth in our most recent and future filings with the Securities and Exchange Commission, actual results could vary significantly from those anticipated in this presentation, and our financial condition and results of operations could be materially adversely affected. This presentation contains trademarks, trade names and service marks of other companies, which are the property of their respective owners.

Certain information contained in this presentation and statements made orally during this presentation relate to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party studies, publications, surveys and other data to be reliable as of the date of the presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent sources has evaluated the reasonableness or accuracy of the Company's internal estimates or research and no reliance should be made on any information or statements made in this presentation relating to or based on such internal estimates and research.


# **Outline of Presentation**

- Kymera's pipeline
- MDM2 is key regulator of p53
- Profile of MDM2 degrader KT-253
- KT-253 in vivo efficacy in ALL and AML xenograft models
- MDM2 dependency across large subset of tumor types
- Summary and outlook

Founded **KYMERA** 2016 0000000 Recognition 2021-BEST PLACES TO WO Partnerships sonofi

# **Introduction to Kymera**






**OUR VISION** 

To be a disease- and technologyagnostic, fully integrated global biopharmaceutical company, using targeted protein degradation to deliver medicines that will transform patients' lives

- Leader in Targeted Protein Degradation (TPD)
- Building a fully-integrated, global biotech company
- Initial focus in Immunology/Inflammation and Oncology, but already a disease-agnostic platform
- Accelerating forward integration through key strategic partnerships
- Executed many "firsts" for TPD with initial clinical programs
- Three clinical stage programs and a deep pipeline positioned to deliver ≥1 IND/year
- Focused on **continued innovation** in platform and discovery
- Well capitalized with over \$600 million of cash as of 8/31/22

# **Kymera's Pipeline of Novel Protein Degraders**



**KYMERA** ©2022 KYMERA THERAPEUTICS, INC.

# We Want to Drug All Target Classes





#### Expanding the Druggable Proteome with TPD




Inadequately Drugged Targets with Clear Degrader Advantage

Small molecule binders exist but unable to drug target fully e.g. IRAK4, MDM2...










Clinically Validated Targets Enabled by E3 Ligase <u>T</u>issue <u>Restricted Expression</u>


On target unwanted pharmacology limits clinical application



Tissue sparing or selective E3 ligases eliminate unwanted toxicity and allow full clinical potential

# MDM2 (KT-253)


# MDM2 is the E3 Ligase that Modulates P53, the Largest Tumor Suppressor




#### **Cancer Genetics**

- p53 is **NOT mutated** in almost 50% of tumors
- MDM2 overexpression and amplification can inactivate p53
- Large opportunity in wide variety of cancers

#### Dependency of $p53^{WT}$ Cells on MDM2



# MDM2 Degradation, Not Inhibition, Efficiently Restores p53




#### **Clinical Validation**

- MDM2 small molecule inhibitors of MDM2/p53 interaction show activity in the clinic..
- ...but they induce MDM2 feedback loop resulting in limited impact on pathway

#### Degrader Advantage


- MDM2 degraders, by removing the protein, can overcome the p53-dependent feedback loop that upregulates MDM2
- MDM2 degrader can induce an acute apoptotic response in tumor cells, increasing efficacy and therapeutic index vs a small molecule inhibitor

# Kymera's MDM-2 Degrader Development Candidate, KT-253 is Superior to MDM2/p53 Small Molecule Inhibitors




- KT-253 is >200-fold more potent in tumor cell killing assays than SMI's due to to its mechanism of action
- Proteomics show selective degradation of KT-253

## KT-253, Unlike Small Molecule Inhibitors, Overcomes the MDM2 and p53 Autoregulatory Feedback Loop




Degrader Overcomes MDM2 Feedback Loop


MDM2 levels are kept at undetectable levels with MDM2 degrader KT-253, leading to p53 stabilization



MDM2 levels are increased by the small molecule inhibitor (feedback loop), impairing p53 stabilization




# KT-253 is Highly Selective MDM2 Degrader that Leads to MDM2 Degradation-Dependent Downstream Activation of p53 Targets




- Deep Tandem Mass Tag proteomics analysis at 8h post KT-253 treatment showed no offtarget degradation in RS4;11 cells at 10x IC<sub>90</sub> concentration
- ~9000 Proteins were monitored
- All upregulated proteins are downstream targets of p53 stabilization
- Due to its very low abundance in RS4;11, MDM2 itself could not be monitored in this study
- Highly sensitive targeted mass spec has been developed to detect MDM2

# Short Term Exposure to MDM2 Degrader, but not SMI, is Sufficient to Commit Cells to Undergo Apoptosis




- 4 hr target coverage by KT-253 is sufficient to induce apoptosis in contrast to SMIs
- Supports hypothesis that intermittent dosing schedule of KT-253 can drive efficacy while increasing therapeutic index

# High Acute Exposures of KT-253 Trigger Acute Apoptotic Response and Tumor Regression in RS4;11 (ALL) Xenograft Model



- Short term high exposures of KT-253 induce apoptosis and cause sustained tumor regression
- DS-3032 MDM2 inhibitor dosed at clinically relevant dose/schedule shows inferior efficacy vs KT-253 at expected tolerated human dose/schedule

# KT-253 Achieves Tumor Regression in MV-4-11 (AML) Xenograft Model




- KT-253 achieves sustained tumor regression in MV-4-11 xenograft model
- MDM2 degradation (KT-253, 3 mg/kg) leads to rapid upregulation of p53 downstream targets

### MDM2 Dependency Seen Across a Large Subset of Tumor Types


Large Franchise Potential in Liquid and Solid Tumors

#### Dependency of p53<sup>WT</sup> Cell Lines on MDM2



**Tumor Types**: Uveal melanoma, Bile Duct, Bladder, Bone, Brain, Breast, Colon, Endometrial/Uterine, Gastric, Kidney, Liver, Lung, Ovarian, Pancreatic, Rhabdoid, Sarcoma, Leukemia, Lymphoma **p53WT cell lines sensitive**: ALL, AML, DLBCL, Uveal Melanoma p53 mutant cell lines were not sensitive to KT-253 or DS-3032 as expected

#### MDM2 Degrader Superior to SMI Across Cell Line Panel



# **KT-253 Summary**

- KT-253 is a potent MDM2 degrader and a best-in-class p53 stabilizer with potential to treat numerous p53 WT tumors
- KT-253 inhibits tumor cell growth with picomolar potency and is >200-fold more potent than clinically active MDM2 small molecule inhibitors
- KT-253, unlike small molecule inhibitors, blocks the feedback loop which up-regulates MDM2 production and in doing so more effectively stabilizes the tumor suppressor p53
- Short term high exposures of KT-253 are enough to induce apoptosis in cell lines and cause sustained tumor regression in ALL and AML xenograft models, which ensures high activity and improved therapeutic index vs SMI's
- Broad franchise opportunities available for this mechanism (p53 WT is present in >50% tumors); Kymera is focused on indications with specific sensitivity to degrader mechanism, such as AML, uveal melanoma and other solid and liquid tumors through a biomarker selection strategy
- Projected IND filing in 2022

**KYMERA** ©2022 KYMERA THERAPEUTICS, INC.

# KYMERA

